Lobbying client

NEKTAR THERAPEUTICS

Bio-pharmaceutical Company

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 5 of its records are shown together here.

Filings
52
Filed by
5
Reported in-house
—
Reported by firms
$2,333,600

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2008 to 2022

Filings

52 filings, newest first.
Filing Filed by Amount
2nd Quarter - Termination
2nd Quarter 2022
BGR GOVERNMENT AFFAIRS — reported
1st Quarter - Report
1st Quarter 2022
BGR GOVERNMENT AFFAIRS $50,000 reported
4th Quarter - Report
4th Quarter 2021
BGR GOVERNMENT AFFAIRS $50,000 reported
3rd Quarter - Report
3rd Quarter 2021
BGR GOVERNMENT AFFAIRS $50,000 reported
2nd Quarter - Report
2nd Quarter 2021
BGR GOVERNMENT AFFAIRS $50,000 reported
1st Quarter - Report
1st Quarter 2021
BGR GOVERNMENT AFFAIRS $50,000 reported
4th Quarter - Report
4th Quarter 2020
BGR GOVERNMENT AFFAIRS $50,000 reported
3rd Quarter - Report
3rd Quarter 2020
BGR GOVERNMENT AFFAIRS $50,000 reported
2nd Quarter - Report
2nd Quarter 2020
BGR GOVERNMENT AFFAIRS $60,000 reported
1st Quarter - Termination
1st Quarter 2020
MANATT, PHELPS, AND PHILLIPS $14,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 27
Pharmacy PHA 25
Homeland Security HOM 1
Chemicals/Chemical Industry CHM 1

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.